{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T07:53:13Z","timestamp":1766908393107},"reference-count":195,"publisher":"BENTHAM SCIENCE PUBLISHERS","isbn-type":[{"value":"9789815179842","type":"print"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,10]]},"abstract":"<jats:p>Affecting more than 50 million people worldwide and with high global costs\nannually, neurological disorders such as Alzheimer's disease (AD) and Parkinson\u2019s\ndisease (PD) are a growing challenge all over the world. Globally, only in 2018, AD\ncosts reached an astonishing $ 1 trillion and, since the annual costs of AD are rapidly\nincreasing, the projections estimate that these numbers will double by 2030.\nConsidering the industrial perspective, the costs related to the development of new\ndrugs are extremely high when compared to the expected financial return. One of the\naggravating factors is the exorbitant values for the synthesis of chemical compounds,\nhindering the process of searching for new drug candidates. In the last 10-year period,\nan average of 20 to 40 new drugs were approved per year, representing a success rate\nof less than 6%. However, the number of referrals for new drug orders and\/or\napplications remained at approximately 700 each year, reinforcing the difficulty in the\nprocess of identifying and developing novel drugs. Regarding neurodegenerative\ndiseases, the FDA (USA) approved 53 new therapies in 2019, including 48 new\nmolecules and, from these, three are medicines and two are vaccines. The main drugs\nrecommended for the treatment of these disorders are included in the following classes:\nDopamine supplement (Levodopa), Monoamine oxidase (MAO) inhibitor (Selegiline,\nRasagiline), Dopamine agonist (Apomorphine, Pramipexole), and Acetylcholinesterase\ninhibitor (Donepezil, Rivastigmine, Galantamine). Additionally, the current\npharmacological treatments are not able to cure these patients and considering the\netiological complexity and the prevalence of neurological disorders, scientists have a great challenge in exploring new therapies and new molecules to find an adequate and\nviable treatment for these diseases. Clinical trials are essential in this process and thus,\nthis chapter describes the most important drugs that were targets of phase III and IV\nclinical studies in the last five years, associated with the most common neurological\ndisorders worldwide, AD and PD. Information about mechanisms of action,\nexperimental studies in other diseases that support their use, and chemical structure of\nthe drugs are included in this chapter. Additionally, nature as a source of valuable\nchemical entities for PD and AD therapeutics was also revised, as well as future\nadvances in the field regarding tracking new drugs to get successful results and critical\nopinions in the research and clinical investigation.<\/jats:p>","DOI":"10.2174\/9789815179842124120003","type":"book-chapter","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T05:07:16Z","timestamp":1710306436000},"page":"1-58","source":"Crossref","is-referenced-by-count":5,"title":["Recent Drugs Tested in Clinical Trials for Alzheimer\u00b4s and Parkinson\u00b4s Diseases Treatment: Current Approaches in Tracking New Drugs"],"prefix":"10.2174","author":[{"given":"Fernanda","family":"Majolo","sequence":"first","affiliation":[{"name":"Graduate Program in Biotechnology, University of Vale do Taquari (Univates), Lajeado, Brazil"}]},{"given":"Lavynia","family":"Ferreira Hoffmann","sequence":"additional","affiliation":[{"name":"Graduate Program in Biotechnology, University of Vale do Taquari (Univates), Lajeado, Brazil"}]},{"given":"Wilian Luan","family":"Pilatti Sant\u2019Ana","sequence":"additional","affiliation":[{"name":"Graduate Program in Medical Sciences, University of Vale do Taquari (Univates), Lajeado,\nBrazil"}]},{"given":"Celso","family":"Alves","sequence":"additional","affiliation":[{"name":"MARE, Marine and Environmental Sciences Centre, ESTM, Polytechnic of Leiria, Peniche,\nPortugal"}]},{"given":"Joana","family":"Silva","sequence":"additional","affiliation":[{"name":"MARE, Marine and Environmental Sciences Centre, ESTM, Polytechnic of Leiria, Peniche,\nPortugal"}]},{"given":"Alice","family":"Martins","sequence":"additional","affiliation":[{"name":"MARE, Marine and Environmental Sciences Centre, ESTM, Polytechnic of Leiria, Peniche,\nPortugal"}]},{"given":"Rui","family":"Pedrosa","sequence":"additional","affiliation":[{"name":"MARE, Marine and Environmental Sciences Centre, ESTM, Polytechnic of Leiria, Peniche,\nPortugal"}]},{"given":"Bruno","family":"Dahmer","sequence":"additional","affiliation":[{"name":"Graduate Program in Biotechnology, University of Vale do Taquari (Univates), Lajeado, Brazil"}]},{"given":"Guilherme","family":"Liberato da Silva","sequence":"additional","affiliation":[{"name":"Graduate Program in Biotechnology, University of Vale do Taquari (Univates), Lajeado, Brazil"}]},{"given":"Lu\u00eds Fernando","family":"Saraiva Macedo Timmers","sequence":"additional","affiliation":[{"name":"Graduate Program in Biotechnology, University of Vale do Taquari (Univates), Lajeado, Brazil"}]},{"given":"M\u00e1rcia","family":"In\u00eas Goettert","sequence":"additional","affiliation":[{"name":"Graduate Program in Biotechnology, University of Vale do Taquari (Univates), Lajeado, Brazil"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/1460-6984.12503","volume":"55","author":"Le H.N.D.","year":"2020","unstructured":"Le H.N.D.; Le L.K.D.; Nguyen P.K.; Mudiyanselage S.B.; Eadie P.; Mensah F.; Sciberras E.; Gold L.; Health-related quality of life, service utilization and costs of low language: A systematic review. Int J Lang Commun Disord 2020,55(1),3-25","journal-title":"Int J Lang Commun Disord"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/ana.24897","volume":"81","author":"Gooch C.L.","year":"2017","unstructured":"Gooch C.L.; Pracht E.; Borenstein A.R.; The burden of neurological disease in the United States: A summary report and call to action. Ann Neurol 2017,81(4),479-484","journal-title":"Ann Neurol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00104-019-01074-w","volume":"91","author":"Verboket R.D.","year":"2020","unstructured":"Verboket R.D.; M\u00fchlenfeld N.; Woschek M.; Marzi I.; Pieper M.; Z\u00f6llner J.P.; Strzelczyk A.; Willems L.M.; Inpatient treatment costs, cost-driving factors and potential reimbursement problems due to fall-related fractures in patients with Parkinson\u2019s disease. Chirurg 2020,91(5),421-427","journal-title":"Chirurg"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/alzrt269","volume":"6","author":"Cummings J.L.","year":"2014","unstructured":"Cummings J.L.; Morstorf T.; Zhong K.; Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 2014,6(4),37","journal-title":"Alzheimers Res Ther"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1602\/neurorx.2.4.683","volume":"2","author":"Gomez-Mancilla B.","year":"2005","unstructured":"Gomez-Mancilla B.; Marrer E.; Kehren J.; Kinnunen A.; Imbert G.; Hillebrand R.; Bergstr\u00f6m M.; Schmidt M.E.; Central nervous system drug development: An integrative biomarker approach toward individualized medicine. NeuroRx 2005,2(4),683-695","journal-title":"NeuroRx"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/S1474-4422(11)70004-7","volume":"10","author":"Craven R.","year":"2011","unstructured":"Craven R.; The risky business of drug development in neurology. Lancet Neurol 2011,10(2),116-117","journal-title":"Lancet Neurol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neuro.2017.03.006","volume":"61","author":"Hersi M.","year":"2017","unstructured":"Hersi M.; Irvine B.; Gupta P.; Gomes J.; Birkett N.; Krewski D.; Risk factors associated with the onset and progression of Alzheimer\u2019s disease: A systematic review of the evidence. Neurotoxicology 2017,61,143-187","journal-title":"Neurotoxicology"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/alz.12068","volume":"16","year":"2020","unstructured":"2020 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 2020,16(3),391-460","journal-title":"Alzheimers Dement"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1146\/annurev-med-092611-084441","volume":"64","author":"Gandy S.","year":"2013","unstructured":"Gandy S.; DeKosky S.T.; Toward the treatment and prevention of Alzheimer\u2019s disease: rational strategies and recent progress. Annu Rev Med 2013,64(1),367-383","journal-title":"Annu Rev Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"McKhann G.M.","year":"2011","unstructured":"McKhann G.M.; Knopman D.S.; Chertkow H.; Hyman B.T.; Jack C.R.; Kawas C.H.; Klunk W.E.; Koroshetz W.J.; Manly J.J.; Mayeux R.; Mohs R.C.; Morris J.C.; Rossor M.N.; Scheltens P.; Carrillo M.C.; Thies B.; Weintraub S.; Phelps C.H.; The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 2011,7(3),263-269","journal-title":"Alzheimers Dement"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s40265-021-01569-z","volume":"81","author":"Dhillon S.","year":"2021","unstructured":"Dhillon S.; Aducanumab: First Approval. Drugs 2021,81(12),1437-1443","journal-title":"Drugs"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1111\/j.1468-1331.2010.03040.x","volume":"17","author":"Hort J.","year":"2010","unstructured":"Hort J.; O\u2019Brien J.T.; Gainotti G.; Pirttila T.; Popescu B.O.; Rektorova I.; Sorbi S.; Scheltens P.; EFNS guidelines for the diagnosis and management of Alzheimer\u2019s disease. Eur J Neurol 2010,17(10),1236-1248","journal-title":"Eur J Neurol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1517\/17425255.1.3.527","volume":"1","author":"Seltzer B.","year":"2005","unstructured":"Seltzer B.; Donepezil: a review. Expert Opin Drug Metab Toxicol 2005,1(3),527-536","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1517\/14656566.8.7.1011","volume":"8","author":"Seltzer B.","year":"2007","unstructured":"Seltzer B.; Donepezil: an update. Expert Opin Pharmacother 2007,8(7),1011-1023","journal-title":"Expert Opin Pharmacother"},{"key":"ref=15","unstructured":""},{"key":"ref=16","first-page":"293","volume":"7","author":"Rogers S.L.","year":"1996","unstructured":"Rogers S.L.; Friedhoff L.T.; The efficacy and safety of donepezil in patients with Alzheimer\u2019s disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. Dementia 1996,7(6),293-303","journal-title":"Dementia"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1212\/WNL.50.1.136","volume":"50","author":"Rogers S.L.","year":"1998","unstructured":"Rogers S.L.; Farlow M.R.; Doody R.S.; Mohs R.; Friedhoff L.T.; A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer\u2019s disease. Neurology 1998,50(1),136-145","journal-title":"Neurology"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000017126","volume":"10","author":"Burns A.","year":"1999","unstructured":"Burns A.; Rossor M.; Hecker J.; Gauthier S.; Petit H.; M\u00f6ller H.J.; Rogers S.L.; Friedhoff L.T.; The effects of donepezil in Alzheimer\u2019s disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999,10(3),237-244","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1124\/jpet.103.050104","volume":"306","author":"Takada Y.","year":"2003","unstructured":"Takada Y.; Yonezawa A.; Kume T.; Katsuki H.; Kaneko S.; Sugimoto H.; Akaike A.; Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther 2003,306(2),772-777","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=20","author":"Kumar A.","year":"2021","unstructured":"Kumar A.; Sidhu J.; Goyal A.; Tsao J.W.; Svercauski J.; Alzheimer Disease (Nursing) 2021","journal-title":"Alzheimer Disease (Nursing)"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1212\/WNL.57.4.613","volume":"57","author":"Feldman H.","year":"2001","unstructured":"Feldman H.; Gauthier S.; Hecker J.; Vellas B.; Subbiah P.; Whalen E.; A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer\u2019s disease. Neurology 2001,57(4),613-620","journal-title":"Neurology"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1001\/archneur.61.12.1852","volume":"61","author":"Seltzer B.","year":"2004","unstructured":"Seltzer B.; Zolnouni P.; Nunez M.; Goldman R.; Kumar D.; Ieni J.; Richardson S.; Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol 2004,61(12),1852-1856","journal-title":"Arch Neurol"},{"key":"ref=23","author":"Tariot P.N.","unstructured":"Tariot P.N.; A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001; 49(12): 1590-9. https:\/\/pubmed.ncbi.nlm.nih.gov\/11843990\/"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1161\/01.STR.0000091396.95360.E1","volume":"34","author":"Black S.","year":"2003","unstructured":"Black S.; Rom\u00e1n G.C.; Geldmacher D.S.; Salloway S.; Hecker J.; Burns A.; Perdomo C.; Kumar D.; Pratt R.; Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003,34(10),2323-2330","journal-title":"Stroke"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1212\/01.WNL.0000078943.50032.FC","volume":"61","author":"Wilkinson D.","year":"2003","unstructured":"Wilkinson D.; Doody R.; Helme R.; Taubman K.; Mintzer J.; Kertesz A.; Pratt R.D.; Donepezil in vascular dementia: A randomized, placebo-controlled study. Neurology 2003,61(4),479-486","journal-title":"Neurology"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/gps.993","volume":"19","author":"Leroi I.","year":"2004","unstructured":"Leroi I.; Brandt J.; Reich S.G.; Lyketsos C.G.; Grill S.; Thompson R.; Marsh L.; Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson\u2019s disease. Int J Geriatr Psychiatry 2004,19(1),1-8","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1136\/jnnp.72.6.708","volume":"72","author":"Aarsland D.","year":"2002","unstructured":"Aarsland D.; Laake K.; Larsen J.P.; Janvin C.; Donepezil for cognitive impairment in Parkinson\u2019s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002,72(6),708-712","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1527-3458.2001.tb00204.x","volume":"7","author":"Shigeta M.","year":"2001","unstructured":"Shigeta M.; Homma A.; Donepezil for Alzheimer\u2019s disease: pharmacodynamic, pharmacokinetic, and clinical profiles. CNS Drug Rev 2001,7(4),353-368","journal-title":"CNS Drug Rev"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3233\/JAD-190940","volume":"74","author":"Jia J.","year":"2020","unstructured":"Jia J.; Wei C.; Chen W.; Jia L.; Zhou A.; Wang F.; Tang Y.; Xu L.; Safety and Efficacy of Donepezil 10 mg\/day in Patients with Mild to Moderate Alzheimer\u2019s Disease. J Alzheimers Dis 2020,74(1),199-211","journal-title":"J Alzheimers Dis"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0166-4328(97)00175-7","volume":"94","author":"Solanto M.V.","year":"1998","unstructured":"Solanto M.V.; Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998,94(1),127-152","journal-title":"Behav Brain Res"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S0025-6196(11)64618-1","volume":"75","author":"Challman T.D.","year":"2000","unstructured":"Challman T.D.; Lipsky J.J.; Methylphenidate: its pharmacology and uses. Mayo Clin Proc 2000,75(7),711-721","journal-title":"Mayo Clin Proc"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/0014-2999(89)90066-6","volume":"166","author":"Hurd Y.L.","year":"1989","unstructured":"Hurd Y.L.; Ungerstedt U.; In vivo neurochemical profile of dopamine uptake inhibitors and releasers in rat caudate-putamen. Eur J Pharmacol 1989,166(2),251-260","journal-title":"Eur J Pharmacol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1176\/ajp.155.10.1325","volume":"155","author":"Volkow N.D.","year":"1998","unstructured":"Volkow N.D.; Wang G.J.; Fowler J.S.; Gatley S.J.; Logan J.; Ding Y.S.; Hitzemann R.; Pappas N.; Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998,155(10),1325-1331","journal-title":"Am J Psychiatry"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1001\/archpsyc.1995.03950180042006","volume":"52","author":"Volkow N.D.","year":"1995","unstructured":"Volkow N.D.; Ding Y.S.; Fowler J.S.; Wang G.J.; Logan J.; Gatley J.S.; Dewey S.; Ashby C.; Liebermann J.; Hitzemann R.; Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 1995,52(6),456-463","journal-title":"Arch Gen Psychiatry"},{"key":"ref=35","first-page":"422","volume":"210","author":"Ferris R.M.","year":"1979","unstructured":"Ferris R.M.; Tang F.L.; Comparison of the effects of the isomers of amphetamine, methylphenidate and deoxypipradrol on the uptake of l-[3H]norepinephrine and [3H]dopamine by synaptic vesicles from rat whole brain, striatum and hypothalamus. J Pharmacol Exp Ther 1979,210(3),422-428","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"PL231","DOI":"10.1016\/0024-3205(96)00052-5","volume":"58","author":"Gatley S.J.","year":"1996","unstructured":"Gatley S.J.; Pan D.; Chen R.; Chaturvedi G.; Ding Y.S.; Affinities of methylphenidate derivatives for dopamine, norepinephrine and serotonin transporters. Life Sci 1996,58(12),PL231-PL239","journal-title":"Life Sci"},{"key":"ref=37","author":"Kadesjo B.","unstructured":"Kadesjo B.; ADHD in Children and Adults. ADHD hos barn och vuxna Stockholm:, (2002)."},{"key":"ref=38","unstructured":"Attention Deficit Hyperactivity Disorder: Diagnosis and Management of ADHD in Children, Young People and Adults - PubMed. Available at: https:\/\/pubmed.ncbi.nlm.nih.gov\/22420012\/. (Accessed: 26th May 2021)."},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"CD012069","DOI":"10.1002\/14651858.CD012069.pub2","volume":"5","author":"Storeb\u00f8 O.J.","year":"2018","unstructured":"Storeb\u00f8 O.J.; Pedersen N.; Ramstad E.; Kielsholm M.L.; Nielsen S.S.; Krogh H.B.; Moreira-Maia C.R.; Magnusson F.L.; Holmskov M.; Gerner T.; Skoog M.; Rosendal S.; Groth C.; Gillies D.; Buch Rasmussen K.; Gauci D.; Zwi M.; Kirubakaran R.; H\u00e5konsen S.J.; Aagaard L.; Simonsen E.; Gluud C.; Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. Cochrane Libr 2018,5(5),CD012069","journal-title":"Cochrane Libr"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2174\/1389450118666170317162603","volume":"19","author":"Andrew B.N.","year":"2018","unstructured":"Andrew B.N.; Guan N.C.; Jaafar N.R.N.; The Use of Methylphenidate for Physical and Psychological Symptoms in Cancer Patients: A Review. Curr Drug Targets 2018,19(8),877-887","journal-title":"Curr Drug Targets"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1200\/JCO.1998.16.7.2522","volume":"16","author":"Meyers C.A.","year":"1998","unstructured":"Meyers C.A.; Weitzner M.A.; Valentine A.D.; Levin V.A.; Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 1998,16(7),2522-2527","journal-title":"J Clin Oncol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1177\/088307389200700425","volume":"7","author":"DeLong R.","year":"1992","unstructured":"DeLong R.; Friedman H.; Friedman N.; Gustafson K.; Oakes J.; Methylphenidate in neuropsychological sequelae of radiotherapy and chemotherapy of childhood brain tumors and leukemia. J Child Neurol 1992,7(4),462-463","journal-title":"J Child Neurol"},{"key":"ref=43","first-page":"100","volume":"30","author":"Gagnon B.","year":"2005","unstructured":"Gagnon B.; Low G.; Schreier G.; Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci 2005,30(2),100-107","journal-title":"J Psychiatry Neurosci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hed.2890080410","volume":"8","author":"Fernandez F.","year":"1986","unstructured":"Fernandez F.; Adams F.; Methylphenidate treatment of patients with head and neck cancer. Head Neck Surg 1986,8(4),296-300","journal-title":"Head Neck Surg"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1176\/jnp.7.3.347","volume":"7","author":"Weitzner M.A.","year":"1995","unstructured":"Weitzner M.A.; Meyers C.A.; Valentine A.D.; Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. J Neuropsychiatry Clin Neurosci 1995,7(3),347-350","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S0193-953X(05)70304-X","volume":"19","author":"Masand P.S.","year":"1996","unstructured":"Masand P.S.; Tesar G.E.; Use of stimulants in the medically ill. Psychiatr Clin North Am 1996,19(3),515-547","journal-title":"Psychiatr Clin North Am"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11912-005-0051-8","volume":"7","author":"Sood A.","year":"2005","unstructured":"Sood A.; Moynihan T.J.; Cancer-related fatigue: An update. Curr Oncol Rep 2005,7(4),277-282","journal-title":"Curr Oncol Rep"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/104990910602300106","volume":"23","author":"Sood A.","year":"2006","unstructured":"Sood A.; Barton D.L.; Loprinzi C.L.; Use of methylphenidate in patients with cancer. Am J Hosp Palliat Care 2006,23(1),35-40","journal-title":"Am J Hosp Palliat Care"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1001\/jamaneurol.2021.3356","volume":"78","author":"Mintzer J.","year":"2021","unstructured":"Mintzer J.; Lanct\u00f4t K.L.; Scherer R.W.; Rosenberg P.B.; Herrmann N.; van Dyck C.H.; Padala P.R.; Brawman-Mintzer O.; Porsteinsson A.P.; Lerner A.J.; Craft S.; Levey A.I.; Burke W.; Perin J.; Shade D.; Kominek V.; Michalak H.; Ni G.; Good S.; Mecca A.; Salem-Spencer S.; Keltz M.; Morales E.; Clark E.D.; Williams A.; Kindy A.; Freeman R.; Jamil N.; Schultz M.; Sami S.; Padala K.P.; Parkes C.; Lah J.; Vaughn P.; Hales C.; Rapoport M.; Gallagher D.; Li A.; Sandra B.; Vieira D.; Ruthirakuhan M.; Babani P.; Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease. JAMA Neurol 2021,78(11),1324-1332","journal-title":"JAMA Neurol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2147\/CIA.S129145","volume":"12","author":"Kandiah N.","year":"2017","unstructured":"Kandiah N.; Pai M.C.; Senanarong V.; Looi I.; Ampil E.; Park K.W.; Karanam A.K.; Christopher S.; Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson\u2019s disease dementia. Clin Interv Aging 2017,12,697-707","journal-title":"Clin Interv Aging"},{"key":"ref=51","unstructured":""},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1474-4422(15)00389-0","volume":"15","author":"Henderson E.J.","year":"2016","unstructured":"Henderson E.J.; Lord S.R.; Brodie M.A.; Gaunt D.M.; Lawrence A.D.; Close J.C.T.; Whone A.L.; Ben-Shlomo Y.; Rivastigmine for gait stability in patients with Parkinson\u2019s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2016,15(3),249-258","journal-title":"Lancet Neurol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1002\/gps.4569","volume":"32","author":"Youn Y.C.","year":"2017","unstructured":"Youn Y.C.; Shin H.W.; Choi B.S.; Kim S.; Lee J.Y.; Ha Y.C.; Rivastigmine patch reduces the incidence of postoperative delirium in older patients with cognitive impairment. Int J Geriatr Psychiatry 2017,32(10),1079-1084","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.neubiorev.2018.01.006","volume":"86","author":"Cotter J.","year":"2018","unstructured":"Cotter J.; Muhlert N.; Talwar A.; Granger K.; Examining the effectiveness of acetylcholinesterase inhibitors and stimulant-based medications for cognitive dysfunction in multiple sclerosis: A systematic review and meta-analysis. Neurosci Biobehav Rev 2018,86,99-107","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40266-018-00636-7","volume":"36","author":"Hershey L.A.","year":"2019","unstructured":"Hershey L.A.; Coleman-Jackson R.; Pharmacological Management of Dementia with Lewy Bodies. Drugs Aging 2019,36(4),309-319","journal-title":"Drugs Aging"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1177\/1039856217734677","volume":"25","author":"Keks N.A.","year":"2017","unstructured":"Keks N.A.; Hope J.; Keogh S.; Suvorexant: scientifically interesting, utility uncertain. Australas Psychiatry 2017,25(6),622-624","journal-title":"Australas Psychiatry"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"5320","DOI":"10.1021\/jm100541c","volume":"53","author":"Cox C.D.","year":"2010","unstructured":"Cox C.D.; Breslin M.J.; Whitman D.B.; Schreier J.D.; McGaughey G.B.; Bogusky M.J.; Roecker A.J.; Mercer S.P.; Bednar R.A.; Lemaire W.; Bruno J.G.; Reiss D.R.; Harrell C.M.; Murphy K.L.; Garson S.L.; Doran S.M.; Prueksaritanont T.; Anderson W.B.; Tang C.; Roller S.; Cabalu T.D.; Cui D.; Hartman G.D.; Young S.D.; Koblan K.S.; Winrow C.J.; Renger J.J.; Coleman P.J.; Discovery of the Dual Orexin Receptor Antagonist [(7 R )-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2 H -1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the Treatment of Insomnia. J Med Chem 2010,53(14),5320-5332","journal-title":"J Med Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40263-012-0036-8","volume":"27","author":"Mieda M.","year":"2013","unstructured":"Mieda M.; Sakurai T.; Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status. CNS Drugs 2013,27(2),83-90","journal-title":"CNS Drugs"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcrc.2020.05.006","volume":"59","author":"Adams A.D.","year":"2020","unstructured":"Adams A.D.; Pepin M.J.; Brown J.N.; The role of suvorexant in the prevention of delirium during acute hospitalization: A systematic review. J Crit Care 2020,59,1-5","journal-title":"J Crit Care"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.09.024","volume":"28","author":"Kawada K.","year":"2019","unstructured":"Kawada K.; Ohta T.; Tanaka K.; Miyamura M.; Tanaka S.; Addition of Suvorexant to Ramelteon Therapy for Improved Sleep Quality with Reduced Delirium Risk in Acute Stroke Patients. J Stroke Cerebrovasc Dis 2019,28(1),142-148","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/alz.12035","volume":"16","author":"Herring W.J.","year":"2020","unstructured":"Herring W.J.; Ceesay P.; Snyder E.; Bliwise D.; Budd K.; Hutzelmann J.; Stevens J.; Lines C.; Michelson D.; Polysomnographic assessment of suvorexant in patients with probable Alzheimer\u2019s disease dementia and insomnia: a randomized trial. Alzheimers Dement 2020,16(3),541-551","journal-title":"Alzheimers Dement"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3350\/cmh.2018.0084","volume":"25","author":"Sharma M.K.","year":"2019","unstructured":"Sharma M.K.; Kainth S.; Kumar S.; Bhardwaj A.; Agarwal H.K.; Maiwall R.; Jamwal K.D.; Shasthry S.M.; Jindal A.; Choudhary A.; Anand L.; Dhamija R.M.; Kumar G.; Sharma B.C.; Sarin S.K.; Effects of zolpidem on sleep parameters in patients with cirrhosis and sleep disturbances: A randomized, placebo-controlled trial. Clin Mol Hepatol 2019,25(2),199-209","journal-title":"Clin Mol Hepatol"},{"key":"ref=63","author":"Kim H. M.","unstructured":"Kim H. M.; Predictors of long-term and high-dose use of zolpidem in veterans. J Clin Psychiatry 2019 Feb 5; 80(2): 18m12149.","journal-title":"J Clin Psychiatry"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/papr.12776","volume":"19","author":"Bjurstr\u00f6m M.F.","year":"2019","unstructured":"Bjurstr\u00f6m M.F.; Irwin M.R.; Perioperative Pharmacological Sleep-Promotion and Pain Control: A Systematic Review. Pain Pract 2019,19(5),552-569","journal-title":"Pain Pract"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1755-5949.2010.00158.x","volume":"17","author":"Dang A.","year":"2011","unstructured":"Dang A.; Garg A.; Rataboli P.V.; Role of zolpidem in the management of insomnia. CNS Neurosci Ther 2011,17(5),387-397","journal-title":"CNS Neurosci Ther"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3389\/fphar.2018.01523","volume":"9","author":"Neumann E.","year":"2019","unstructured":"Neumann E.; Rudolph U.; Knutson D.E.; Li G.; Cook J.M.; Hentschke H.; Antkowiak B.; Drexler B.; Zolpidem activation of alpha 1-containing GABAA receptors selectively inhibits high frequency action potential firing of cortical neurons. Front Pharmacol 2019,9,1523","journal-title":"Front Pharmacol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4103\/atm.ATM_198_18","volume":"14","author":"Nigam G.","year":"2019","unstructured":"Nigam G.; Camacho M.; Riaz M.; The effect of nonbenzodiazepines sedative hypnotics on apnea\u2013hypopnea index: A meta-analysis. Ann Thorac Med 2019,14(1),49-55","journal-title":"Ann Thorac Med"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1517\/14656566.2012.667074","volume":"13","author":"Greenblatt D.J.","year":"2012","unstructured":"Greenblatt D.J.; Roth T.; Zolpidem for insomnia. Expert Opin Pharmacother 2012,13(6),879-893","journal-title":"Expert Opin Pharmacother"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2165\/00023210-200519010-00008","volume":"19","author":"Swainston Harrison T.","year":"2005","unstructured":"Swainston Harrison T.; Keating G.M.; Zolpidem. CNS Drugs 2005,19(1),65-89","journal-title":"CNS Drugs"},{"key":"ref=70","unstructured":"Zolpidem - StatPearls - NCBI Bookshelf. Available at: . (Accessed: 26th May 2021)"},{"key":"ref=71","first-page":"1","author":"Buscemi N.","year":"2005","unstructured":"Buscemi N.; Vandermeer B.; Friesen C.; Bialy L.; Tubman M.; Ospina M.; Klassen T.P.; Witmans M.; Manifestations and management of chronic insomnia in adults. Evid Rep Technol Assess (Summ) 2005 (125),1-10","journal-title":"Evid Rep Technol Assess (Summ)"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1001\/jamaneurol.2017.1133","volume":"74","author":"Bomalaski M.N.","year":"2017","unstructured":"Bomalaski M.N.; Claflin E.S.; Townsend W.; Peterson M.D.; Zolpidem for the treatment of neurologic disorders: A systematic review. JAMA Neurol 2017,74(9),1130-1139","journal-title":"JAMA Neurol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1080\/17512433.2017.1347502","volume":"10","author":"Noormandi A.","year":"2017","unstructured":"Noormandi A.; Shahrokhi M.; Khalili H.; Potential benefits of zolpidem in disorders of consciousness. Expert Rev Clin Pharmacol 2017,10(9),983-992","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2165\/00002512-199303050-00006","volume":"3","author":"Wadworth A.N.","year":"1993","unstructured":"Wadworth A.N.; McTavish D.; Zopiclone. Drugs Aging 1993,3(5),441-459","journal-title":"Drugs Aging"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"117s","DOI":"10.1016\/0924-9338(96)80093-9","volume":"10","author":"D\u00f6ble A.","year":"1995","unstructured":"D\u00f6ble A.; Canton T.; Malgouris C.; Stutzmann J.M.; Piot O.; Bardone M.C.; Pauchet C.; Blanchard J.C.; The mechanism of action of zopiclone. Eur Psychiatry 1995,10(S3)(Suppl. 3),117s-128s","journal-title":"Eur Psychiatry"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2165\/00023210-200317070-00004","volume":"17","author":"Hesse L.M.","year":"2003","unstructured":"Hesse L.M.; von Moltke L.L.; Greenblatt D.J.; Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs 2003,17(7),513-532","journal-title":"CNS Drugs"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s11325-014-1084-8","volume":"19","author":"Holmedahl N.H.","year":"2015","unstructured":"Holmedahl N.H.; \u00d8verland B.; Fondenes O.; Ellingsen I.; Hardie J.A.; Zopiclone effects on breathing at sleep in stable chronic obstructive pulmonary disease. Sleep Breath 2015,19(3),921-930","journal-title":"Sleep Breath"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"5","DOI":"10.6061\/clinics\/2016(01)02","volume":"71","author":"Pinto L.R.","year":"2016","unstructured":"Pinto L.R.; Bittencourt L.R.A.; Treptow E.C.; Braga L.R.; Tufik S.; Eszopiclone versus zopiclone in the treatment of insomnia. Clinics (S\u00e3o Paulo) 2016,71(1),5-9","journal-title":"Clinics (S\u00e3o Paulo)"},{"key":"ref=79","first-page":"69","volume":"5","author":"Ponciano E.","year":"1990","unstructured":"Ponciano E.; Freitas F.; Camara J.; Faria M.; Barreto M.; Hindmarch I.; A comparison of the efficacy, tolerance and residual effects of zopiclone, flurazepam and placebo in insomniac outpatients. Int Clin Psychopharmacol 1990,5(Suppl. 2),69-77","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41386-021-01191-3","volume":"47","author":"Louzada L.L.","year":"2022","unstructured":"Louzada L.L.; Machado F.V.; Quintas J.L.; Ribeiro G.A.; Silva M.V.; Mendon\u00e7a-Silva D.L.; Gon\u00e7alves B.S.B.; N\u00f3brega O.T.; Camargos E.F.; The efficacy and safety of zolpidem and zopiclone to treat insomnia in Alzheimer\u2019s disease: a randomized, triple-blind, placebo-controlled trial. Neuropsychopharmacology 2022,47(2),570-579","journal-title":"Neuropsychopharmacology"},{"key":"ref=81","unstructured":"Axsome Therapeutics receives FDA fast track designation for axs-05 for alzheimer\u2019s disease agitation."},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.trci.2019.02.005","volume":"5","author":"Lopez Lopez C.","year":"2019","unstructured":"Lopez Lopez C.; Tariot P.N.; Caputo A.; Langbaum J.B.; Liu F.; Riviere M.E.; Langlois C.; Rouzade-Dominguez M.L.; Zalesak M.; Hendrix S.; Thomas R.G.; Viglietta V.; Lenz R.; Ryan J.M.; Graf A.; Reiman E.M.; The Alzheimer\u2019s Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer\u2019s disease. Alzheimers Dement (N Y) 2019,5(1),216-227","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=83","first-page":"242","volume":"4","author":"Lopez Lopez C.","year":"2017","unstructured":"Lopez Lopez C.; Caputo A.; Liu F.; Riviere M.E.; Rouzade-Dominguez M.L.; Thomas R.G.; Langbaum J.B.; Lenz R.; Reiman E.M.; Graf A.; Tariot P.N.; The Alzheimer\u2019s Prevention Initiative Generation Program: Evaluating CNP520 Efficacy in the Prevention of Alzheimer\u2019s Disease. J Prev Alzheimers Dis 2017,4(4),242-246","journal-title":"J Prev Alzheimers Dis"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/mds.26839","volume":"32","author":"Savica R.","year":"2017","unstructured":"Savica R.; Grossardt B.R.; Bower J.H.; Ahlskog J.E.; Mielke M.M.; Rocca W.A.; Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study. Mov Disord 2017,32(2),227-234","journal-title":"Mov Disord"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","volume":"91","author":"Jankovic J.","year":"2020","unstructured":"Jankovic J.; Tan E.K.; Parkinson\u2019s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 2020,91(8),795-808","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"Postuma R.B.","year":"2015","unstructured":"Postuma R.B.; Berg D.; Stern M.; Poewe W.; Olanow C.W.; Oertel W.; Obeso J.; Marek K.; Litvan I.; Lang A.E.; Halliday G.; Goetz C.G.; Gasser T.; Dubois B.; Chan P.; Bloem B.R.; Adler C.H.; Deuschl G.; MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 2015,30(12),1591-1601","journal-title":"Mov Disord"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"Dorsey E.R.","year":"2018","unstructured":"Dorsey E.R.; Elbaz A.; Nichols E.; Abbasi N.; Abd-Allah F.; Abdelalim A.; Adsuar J.C.; Ansha M.G.; Brayne C.; Choi J-Y.J.; Collado-Mateo D.; Dahodwala N.; Do H.P.; Edessa D.; Endres M.; Fereshtehnejad S-M.; Foreman K.J.; Gankpe F.G.; Gupta R.; Hamidi S.; Hankey G.J.; Hay S.I.; Hegazy M.I.; Hibstu D.T.; Kasaeian A.; Khader Y.; Khalil I.; Khang Y-H.; Kim Y.J.; Kokubo Y.; Logroscino G.; Massano J.; Mohamed Ibrahim N.; Mohammed M.A.; Mohammadi A.; Moradi-Lakeh M.; Naghavi M.; Nguyen B.T.; Nirayo Y.L.; Ogbo F.A.; Owolabi M.O.; Pereira D.M.; Postma M.J.; Qorbani M.; Rahman M.A.; Roba K.T.; Safari H.; Safiri S.; Satpathy M.; Sawhney M.; Shafieesabet A.; Shiferaw M.S.; Smith M.; Szoeke C.E.I.; Tabar\u00e9s-Seisdedos R.; Truong N.T.; Ukwaja K.N.; Venketasubramanian N.; Villafaina S.; weldegwergs K.; Westerman R.; Wijeratne T.; Winkler A.S.; Xuan B.T.; Yonemoto N.; Feigin V.L.; Vos T.; Murray C.J.L.; Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018,17(11),939-953","journal-title":"Lancet Neurol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mds.25249","volume":"28","author":"Singleton A.B.","year":"2013","unstructured":"Singleton A.B.; Farrer M.J.; Bonifati V.; The genetics of Parkinson\u2019s disease: Progress and therapeutic implications. Mov Disord 2013,28(1),14-23","journal-title":"Mov Disord"},{"key":"ref=89","unstructured":"Parkinson\u2019s disease in adults NICE guideline. (2017)."},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"Fox S.H.","year":"2018","unstructured":"Fox S.H.; Katzenschlager R.; Lim S.Y.; Barton B.; de Bie R.M.A.; Seppi K.; Coelho M.; Sampaio C.; International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord 2018,33(8),1248-1266","journal-title":"Mov Disord"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s00702-018-1853-9","volume":"125","author":"Sz\u00f6k\u0151 \u00c9.","year":"2018","unstructured":"Sz\u00f6k\u0151 \u00c9.; T\u00e1bi T.; Riederer P.; V\u00e9csei L.; Magyar K.; Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson\u2019s disease. J Neural Transm (Vienna) 2018,125(11),1735-1749","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"574652","DOI":"10.3389\/fnins.2020.574652","volume":"14","author":"Li C.","year":"2020","unstructured":"Li C.; Xue L.; Liu Y.; Yang Z.; Chi S.; Xie A.; Zonisamide for the Treatment of Parkinson Disease: A Current Update. Front Neurosci 2020,14,574652","journal-title":"Front Neurosci"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.27602","volume":"34","author":"Seppi K.","year":"2019","unstructured":"Seppi K.; Ray Chaudhuri K.; Coelho M.; Fox S.H.; Katzenschlager R.; Perez Lloret S.; Weintraub D.; Sampaio C.; Chahine L.; Hametner E-M.; Heim B.; Lim S-Y.; Poewe W.; Djamshidian-Tehrani A.; Update on treatments for nonmotor symptoms of Parkinson\u2019s disease\u2014an evidence-based medicine review. Mov Disord 2019,34(2),180-198","journal-title":"Mov Disord"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"G138","DOI":"10.1152\/ajpgi.00060.2002","volume":"284","author":"Mabley J.G.","year":"2003","unstructured":"Mabley J.G.; Pacher P.; Liaudet L.; Soriano F.G.; Hask\u00f3 G.; Marton A.; Szab\u00f3 C.; Salzman A.L.; Inosine reduces inflammation and improves survival in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol 2003,284(1),G138-G144","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.tips.2004.01.006","volume":"25","author":"Hask\u00f3 G.","year":"2004","unstructured":"Hask\u00f3 G.; Sitkovsky M.V.; Szab\u00f3 C.; Immunomodulatory and neuroprotective effects of inosine. Trends Pharmacol Sci 2004,25(3),152-157","journal-title":"Trends Pharmacol Sci"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1001\/jama.2021.10207","volume":"326","author":"Bluett B.","year":"2021","unstructured":"Bluett B.; Togasaki D.M.; Mihaila D.; Evatt M.; Rezak M.; Jain S.; Schwarzschild M.A.; Ascherio A.; Casaceli C.; Curhan G.C.; Fitzgerald R.; Kamp C.; Lungu C.; Macklin E.A.; Marek K.; Mozaffarian D.; Oakes D.; Rudolph A.; Shoulson I.; Videnovic A.; Scott B.; Gauger L.; Aldred J.; Bixby M.; Ciccarello J.; Gunzler S.A.; Henchcliffe C.; Brodsky M.; Keith K.; Hauser R.A.; Goetz C.; LeDoux M.S.; Hinson V.; Kumar R.; Espay A.J.; Jimenez-Shahed J.; Hunter C.; Christine C.; Daley A.; Leehey M.; de Marcaida J.A.; Friedman J.H.; Hung A.; Bwala G.; Litvan I.; Simon D.K.; Simuni T.; Poon C.; Schiess M.C.; Chou K.; Park A.; Bhatti D.; Peterson C.; Criswell S.R.; Rosenthal L.; Durphy J.; Shill H.A.; Mehta S.H.; Ahmed A.; Deik A.F.; Fang J.Y.; Stover N.; Zhang L.; Dewey R.B.; Gerald A.; Boyd J.T.; Houston E.; Suski V.; Mosovsky S.; Cloud L.; Shah B.B.; Saint-Hilaire M.; James R.; Zauber S.E.; Reich S.; Shprecher D.; Pahwa R.; Langhammer A.; LaFaver K.; LeWitt P.A.; Kaminski P.; Goudreau J.; Russell D.; Houghton D.J.; Laroche A.; Thomas K.; McGraw M.; Mari Z.; Serrano C.; Blindauer K.; Rabin M.; Kurlan R.; Morgan J.C.; Soileau M.; Ainslie M.; Bodis-Wollner I.; Schneider R.B.; Waters C.; Ratel A.S.; Beck C.A.; Bolger P.; Callahan K.F.; Crotty G.F.; Klements D.; Kostrzebski M.; McMahon G.M.; Pothier L.; Waikar S.S.; Lang A.; Mestre T.; Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression. JAMA 2021,326(10),926-939","journal-title":"JAMA"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00213-019-05419-5","volume":"237","author":"Teixeira F.C.","year":"2020","unstructured":"Teixeira F.C.; Gutierres J.M.; Soares M.S.P.; da Siveira de Mattos B.; Spohr L.; do Couto C.A.T.; Bona N.P.; Assmann C.E.; Morsch V.M.; da Cruz I.B.M.; Stefanello F.M.; Spanevello R.M.; Inosine protects against impairment of memory induced by experimental model of Alzheimer disease: a nucleoside with multitarget brain actions. Psychopharmacology (Berl) 2020,237(3),811-823","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/acn3.671","volume":"5","author":"Nicholson K.","year":"2018","unstructured":"Nicholson K.; Chan J.; Macklin E.A.; Levine-Weinberg M.; Breen C.; Bakshi R.; Grasso D.L.; Wills A.M.; Jahandideh S.; Taylor A.A.; Beaulieu D.; Ennist D.L.; Andronesi O.; Ratai E.M.; Schwarzschild M.A.; Cudkowicz M.; Paganoni S.; Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis. Ann Clin Transl Neurol 2018,5(12),1522-1533","journal-title":"Ann Clin Transl Neurol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00702-008-0102-z","volume":"115","author":"Schmidt W.J.","year":"2008","unstructured":"Schmidt W.J.; Lebsanft H.; Heindl M.; Gerlach M.; Gruenblatt E.; Riederer P.; Mayerhofer A.; Scheller D.K.A.; Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements. J Neural Transm (Vienna) 2008,115(10),1385-1392","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"594387","DOI":"10.3389\/fphar.2020.594387","volume":"11","author":"Li K.","year":"2020","unstructured":"Li K.; Zhang Y.; Tian E.; Liu Z.; Wang T.; Fu F.; The Effect of Rotigotine Extended-Release Microspheres Alone or With Celecoxib on the Inflammatory Pain. Front Pharmacol 2020,11,594387","journal-title":"Front Pharmacol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1080\/14656566.2018.1480721","volume":"19","author":"Woitalla D.","year":"2018","unstructured":"Woitalla D.; Dunac A.; Safavi A.; Ceravolo M.G.; Gomez Esteban J.C.; Pavese N.; Asgharnejad M.; Joeres L.; Schuller J.C.; Chaudhuri K.R.; A noninterventional study evaluating the effectiveness of rotigotine and levodopa combination therapy in younger versus older patients with Parkinson\u2019s disease. Expert Opin Pharmacother 2018,19(9),937-945","journal-title":"Expert Opin Pharmacother"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/DDDT.S240862","volume":"15","author":"Soogrim V.","year":"2021","unstructured":"Soogrim V.; Ruberto V.L.; Murrough J.; Jha M.K.; Spotlight on pimavanserin tartrate and its therapeutic potential in the treatment of major depressive disorder: The evidence to date. Drug Des Devel Ther 2021,15,151-157","journal-title":"Drug Des Devel Ther"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1080\/17512433.2017.1369405","volume":"10","author":"Kianirad Y.","year":"2017","unstructured":"Kianirad Y.; Simuni T.; Pimavanserin, a novel antipsychotic for management of Parkinson\u2019s disease psychosis. Expert Rev Clin Pharmacol 2017,10(11),1161-1168","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1474-4422(18)30039-5","volume":"17","author":"Ballard C.","year":"2018","unstructured":"Ballard C.; Banister C.; Khan Z.; Cummings J.; Demos G.; Coate B.; Youakim J.M.; Owen R.; Stankovic S.; Tomkinson E.B.; McDermid J.; Ocal D.; Testad I.; Qayyum M.A.; Kemos\u2019 P.; Borejko O.; Megalogeni M.; Brookes E.V.; Petrava A.; Da Silva M.; Nunez K.; Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer\u2019s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol 2018,17(3),213-222","journal-title":"Lancet Neurol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1586\/14779072.2015.1057504","volume":"13","author":"Kaufmann H.","year":"2015","unstructured":"Kaufmann H.; Norcliffe-Kaufmann L.; Palma J.A.; Droxidopa in neurogenic orthostatic hypotension. Expert Rev Cardiovasc Ther 2015,13(8),875-891","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/WNF.0000000000000168","volume":"39","author":"Hauser R.A.","year":"2016","unstructured":"Hauser R.A.; Heritier S.; Rowse G.J.; Hewitt L.A.; Isaacson S.H.; Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension. Clin Neuropharmacol 2016,39(5),220-226","journal-title":"Clin Neuropharmacol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1097\/MJT.0000000000000468","volume":"24","author":"Ruzieh M.","year":"2017","unstructured":"Ruzieh M.; Dasa O.; Pacenta A.; Karabin B.; Grubb B.; Droxidopa in the treatment of postural orthostatic tachycardia syndrome. Am J Ther 2017,24(2),e157-e161","journal-title":"Am J Ther"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2165\/00002512-199812060-00007","volume":"12","author":"Dooley M.","year":"1998","unstructured":"Dooley M.; Markham A.; Pramipexole. Drugs Aging 1998,12(6),495-514","journal-title":"Drugs Aging"},{"key":"ref=109","unstructured":"Pramipexole - StatPearls - NCBI Bookshelf. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/ NBK557539\/"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"102691","DOI":"10.1016\/j.ajp.2021.102691","volume":"61","author":"Jiang D.Q.","year":"2021","unstructured":"Jiang D.Q.; Jiang L.L.; Wang Y.; Li M.X.; The role of pramipexole in the treatment of patients with depression and Parkinson\u2019s disease: A meta-analysis of randomized controlled trials. Asian J Psychiatr 2021,61,102691","journal-title":"Asian J Psychiatr"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/acps.13055","volume":"140","author":"Tundo A.","year":"2019","unstructured":"Tundo A.; Filippis R.; De Crescenzo F.; Pramipexole in the treatment of unipolar and bipolar depression. A systematic review and meta-analysis. Acta Psychiatr Scand 2019,140(2),116-125","journal-title":"Acta Psychiatr Scand"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1080\/17460441.2020.1767580","volume":"15","author":"Ettcheto M.","year":"2020","unstructured":"Ettcheto M.; Busquets O.; S\u00e1nchez-Lopez E.; Cano A.; Manzine P.R.; Verdaguer E.; Olloquequi J.; Auladell C.; Folch J.; Camins A.; The preclinical discovery and development of opicapone for the treatment of Parkinson\u2019s disease. Expert Opin Drug Discov 2020,15(9),993-1003","journal-title":"Expert Opin Drug Discov"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1002\/mds.27475","volume":"33","author":"Fabbri M.","year":"2018","unstructured":"Fabbri M.; Ferreira J.J.; Lees A.; Stocchi F.; Poewe W.; Tolosa E.; Rascol O.; Opicapone for the treatment of Parkinson\u2019s disease: A review of a new licensed medicine. Mov Disord 2018,33(10),1528-1539","journal-title":"Mov Disord"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.drudis.2018.01.033","volume":"23","author":"Teixeira F.G.","year":"2018","unstructured":"Teixeira F.G.; Gago M.F.; Marques P.; Moreira P.S.; Magalh\u00e3es R.; Sousa N.; Salgado A.J.; Safinamide: a new hope for Parkinson\u2019s disease? Drug Discov Today 2018,23(3),736-744","journal-title":"Drug Discov Today"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1212\/WNL.67.7_suppl_2.S18","volume":"67","author":"Caccia C.","year":"2006","unstructured":"Caccia C.; Maj R.; Calabresi M.; Maestroni S.; Faravelli L.; Curatolo L.; Salvati P.; Fariello R.G.; Safinamide: From molecular targets to a new anti-Parkinson drug. Neurology 2006,67(7, Supplement 2)(Suppl. 2),S18-S23","journal-title":"Neurology"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s40265-015-0389-7","volume":"75","author":"Deeks E.D.","year":"2015","unstructured":"Deeks E.D.; Safinamide: first global approval. Drugs 2015,75(6),705-711","journal-title":"Drugs"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/mds.25751","volume":"29","author":"Borgohain R.","year":"2014","unstructured":"Borgohain R.; Szasz J.; Stanzione P.; Meshram C.; Bhatt M.; Chirilineau D.; Stocchi F.; Lucini V.; Giuliani R.; Forrest E.; Rice P.; Anand R.; Randomized trial of safinamide add-on to levodopa in Parkinson\u2019s disease with motor fluctuations. Mov Disord 2014,29(2),229-237","journal-title":"Mov Disord"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/mds.28219","volume":"35","author":"Choi J.H.","year":"2020","unstructured":"Choi J.H.; Lee J.Y.; Cho J.W.; Koh S.B.; Yang Y.S.; Yoo D.; Shin C.M.; Kim H.T.; Double-Blind, Randomized, Placebo-Controlled Trial of DA -9701 in Parkinson\u2019s Disease: PASS - GI Study. Mov Disord 2020,35(11),1966-1976","journal-title":"Mov Disord"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s12640-020-00246-5","volume":"38","author":"Xu T.","year":"2020","unstructured":"Xu T.; Sun R.; Wei G.; Kong S.; The Protective Effect of Safinamide in Ischemic Stroke Mice and a Brain Endothelial Cell Line. Neurotox Res 2020,38(3),733-740","journal-title":"Neurotox Res"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ejmech.2013.12.028","volume":"75","author":"Bautista-Aguilera O.M.","year":"2014","unstructured":"Bautista-Aguilera O.M.; Esteban G.; Bolea I.; Nikolic K.; Agbaba D.; Moraleda I.; Iriepa I.; Samadi A.; Soriano E.; Unzeta M.; Marco-Contelles J.; Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil\u2013indolyl hybrids as multipotent cholinesterase\/monoamine oxidase inhibitors for the potential treatment of Alzheimer\u2019s disease. Eur J Med Chem 2014,75,82-95","journal-title":"Eur J Med Chem"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4062\/biomolther.2012.096","volume":"21","author":"Kwon Y.S.","year":"2013","unstructured":"Kwon Y.S.; Son M.; DA-9701: A new multi-acting drug for the treatment of functional dyspepsia. Biomol Ther (Seoul) 2013,21(3),181-189","journal-title":"Biomol Ther (Seoul)"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3390\/ph11020044","volume":"11","author":"Dur\u00e3es F.","year":"2018","unstructured":"Dur\u00e3es F.; Pinto M.; Sousa E.; Old drugs as new treatments for neurodegenerative diseases. Pharmaceuticals (Basel) 2018,11(2),44","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1021\/acs.jnatprod.5b01055","volume":"79","author":"Newman D.J.","year":"2016","unstructured":"Newman D.J.; Cragg G.M.; Natural Products as Sources of New Drugs from 1981 to 2014. J Nat Prod 2016,79(3),629-661","journal-title":"J Nat Prod"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.jsps.2018.02.015","volume":"26","author":"Khan R.A.","year":"2018","unstructured":"Khan R.A.; Natural products chemistry: The emerging trends and prospective goals. Saudi Pharm J 2018,26(5),739-753","journal-title":"Saudi Pharm J"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3389\/fphar.2018.00777","volume":"9","author":"Alves C.","year":"2018","unstructured":"Alves C.; Silva J.; Pinteus S.; Gaspar H.; Alpoim M.C.; Botana L.M.; Pedrosa R.; From marine origin to therapeutics: The antitumor potential of marine algae-derived compounds. Front Pharmacol 2018,9,777","journal-title":"Front Pharmacol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3390\/metabo2020303","volume":"2","author":"Dias D.A.","year":"2012","unstructured":"Dias D.A.; Urban S.; Roessner U.; A historical overview of natural products in drug discovery. Metabolites 2012,2(2),303-336","journal-title":"Metabolites"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","volume":"20","author":"Atanasov A.G.","year":"2021","unstructured":"Atanasov A.G.; Zotchev S.B.; Dirsch V.M.; Supuran C.T.; Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov 2021,20(3),200-216","journal-title":"Nat Rev Drug Discov"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/648740","volume":"2014","author":"Xie A.","year":"2014","unstructured":"Xie A.; Gao J.; Xu L.; Meng D.; Shared mechanisms of neurodegeneration in Alzheimer\u2019s disease and Parkinson\u2019s disease. BioMed Res Int 2014,2014,1-8","journal-title":"BioMed Res Int"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.3390\/molecules24081519","volume":"24","author":"Habtemariam S.","year":"2019","unstructured":"Habtemariam S.; Natural products in Alzheimer\u2019s disease therapy: Would old therapeutic approaches fix the broken promise of modern medicines? Molecules 2019,24(8),1519","journal-title":"Molecules"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S1875-5364(17)30013-4","volume":"14","author":"Li J.","year":"2016","unstructured":"Li J.; Larregieu C.A.; Benet L.Z.; Classification of natural products as sources of drugs according to the biopharmaceutics drug disposition classification system (BDDCS). Chin J Nat Med 2016,14(12),888-897","journal-title":"Chin J Nat Med"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"849","DOI":"10.2174\/1570159X15666171129102042","volume":"16","author":"Zanni R.","year":"2018","unstructured":"Zanni R.; Garcia-Domenech R.; Galvez-Llompart M.; Galvez J.; Alzheimer: A Decade of Drug Design. Why Molecular Topology can be an Extra Edge? Curr Neuropharmacol 2018,16(6),849-864","journal-title":"Curr Neuropharmacol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2174\/18715273113129990103","volume":"13","author":"Caraci F.","year":"2014","unstructured":"Caraci F.; Castellano S.; Salomone S.; Drago F.; Bosco P.; Nuovo S.; Searching for disease-modifying drugs in AD: can we combine neuropsychological tools with biological markers? CNS Neurol Disord Drug Targets 2014,13(1),173-186","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"571185","DOI":"10.3389\/fnagi.2020.571185","volume":"12","author":"Troncoso-Escudero P.","year":"2020","unstructured":"Troncoso-Escudero P.; Sepulveda D.; P\u00e9rez-Arancibia R.; Parra A.V.; Arcos J.; Grunenwald F.; Vidal R.L.; On the Right Track to Treat Movement Disorders: Promising Therapeutic Approaches for Parkinson\u2019s and Huntington\u2019s Disease. Front Aging Neurosci 2020,12,571185","journal-title":"Front Aging Neurosci"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3389\/fimmu.2020.00456","volume":"11","author":"Hampel H.","year":"2020","unstructured":"Hampel H.; Caraci F.; Cuello A.C.; Caruso G.; Nistic\u00f2 R.; Corbo M.; Baldacci F.; Toschi N.; Garaci F.; Chiesa P.A.; Verdooner S.R.; Akman-Anderson L.; Hern\u00e1ndez F.; \u00c1vila J.; Emanuele E.; Valenzuela P.L.; Luc\u00eda A.; Watling M.; Imbimbo B.P.; Vergallo A.; Lista S.; A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer\u2019s Disease. Front Immunol 2020,11,456","journal-title":"Front Immunol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.2174\/1381612824666180607124038","volume":"24","author":"Carpenter K.A.","year":"2018","unstructured":"Carpenter K.A.; Huang X.; Machine Learning-based Virtual Screening and Its Applications to Alzheimer\u2019s Drug Discovery: A Review. Curr Pharm Des 2018,24(28),3347-3358","journal-title":"Curr Pharm Des"},{"key":"ref=136","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7404-7_4","author":"Basile L.","year":"2018","unstructured":"Basile L.; Neuromethods 132, 107\u2013137 2018","journal-title":"Neuromethods 132, 107\u2013137"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3390\/ijms20030719","volume":"20","author":"Van Bulck M.","year":"2019","unstructured":"Van Bulck M.; Sierra-Magro A.; Alarcon-Gil J.; Perez-Castillo A.; Morales-Garcia J.; Novel approaches for the treatment of alzheimer\u2019s and parkinson\u2019s disease. Int J Mol Sci 2019,20(3),719","journal-title":"Int J Mol Sci"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/14756366.2016.1250753","volume":"32","author":"Sonmez F.","year":"2017","unstructured":"Sonmez F.; Zengin Kurt B.; Gazioglu I.; Basile L.; Dag A.; Cappello V.; Ginex T.; Kucukislamoglu M.; Guccione S.; Design, synthesis and docking study of novel coumarin ligands as potential selective acetylcholinesterase inhibitors. J Enzyme Inhib Med Chem 2017,32(1),285-297","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.4155\/fmc-2017-0201","volume":"10","author":"de Almeida J.R.","year":"2018","unstructured":"de Almeida J.R.; Figueiro M.; Almeida W.P.; de Paula da Silva C.H.T.; Discovery of novel dual acetylcholinesterase inhibitors with antifibrillogenic activity related to Alzheimer\u2019s disease. Future Med Chem 2018,10(9),1037-1053","journal-title":"Future Med Chem"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3389\/fnins.2016.00294","volume":"10","author":"Marco-Contelles J.","year":"2016","unstructured":"Marco-Contelles J.; Unzeta M.; Bolea I.; Esteban G.; Ramsay R.R.; Romero A.; Mart\u00ednez-Murillo R.; Carreiras M.C.; Ismaili L.; ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer\u2019s Disease Therapy. Front Neurosci 2016,10,294","journal-title":"Front Neurosci"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1503\/jpn.150209","volume":"42","author":"Serrano M.P.","year":"2017","unstructured":"Serrano M.P.; Herrero-Labrador R.; Futch H.S.; Serrano J.; Romero A.; Fernandez A.P.; Samadi A.; Unzeta M.; Marco-Contelles J.; Mart\u00ednez-Murillo R.; The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease. J Psychiatry Neurosci 2017,42(1),59-69","journal-title":"J Psychiatry Neurosci"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"e92750","DOI":"10.1371\/journal.pone.0092750","volume":"9","author":"Wang J.","year":"2014","unstructured":"Wang J.; Land D.; Ono K.; Galvez J.; Zhao W.; Vempati P.; Steele J.W.; Cheng A.; Yamada M.; Levine S.; Mazzola P.; Pasinetti G.M.; Molecular topology as novel strategy for discovery of drugs with a\u03b2 lowering and anti-aggregation dual activities for Alzheimer\u2019s disease. PLoS One 2014,9(3),e92750","journal-title":"PLoS One"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00401-018-1846-7","volume":"136","author":"Hong W.","year":"2018","unstructured":"Hong W.; Wang Z.; Liu W.; O\u2019Malley T.T.; Jin M.; Willem M.; Haass C.; Frosch M.P.; Walsh D.M.; Diffusible, highly bioactive oligomers represent a critical minority of soluble A\u03b2 in Alzheimer\u2019s disease brain. Acta Neuropathol 2018,136(1),19-40","journal-title":"Acta Neuropathol"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"fcab147","DOI":"10.1093\/braincomms\/fcab147","volume":"3","author":"Sideris D.I.","year":"2021","unstructured":"Sideris D.I.; Danial J.S.H.; Emin D.; Ruggeri F.S.; Xia Z.; Zhang Y.P.; Lobanova E.; Dakin H.; De S.; Miller A.; Sang J.C.; Knowles T.P.J.; Vendruscolo M.; Fraser G.; Crowther D.; Klenerman D.; Soluble amyloid beta-containing aggregates are present throughout the brain at early stages of Alzheimer\u2019s disease. Brain Commun 2021,3(3),fcab147","journal-title":"Brain Commun"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejps.2016.04.012","volume":"89","author":"Lin C.H.","year":"2016","unstructured":"Lin C.H.; Hsieh Y.S.; Wu Y.R.; Hsu C.J.; Chen H.C.; Huang W.H.; Chang K.H.; Hsieh-Li H.M.; Su M.T.; Sun Y.C.; Lee G.C.; Lee-Chen G.J.; Identifying GSK-3\u03b2 kinase inhibitors of Alzheimer\u2019s disease: Virtual screening, enzyme, and cell assays. Eur J Pharm Sci 2016,89,11-19","journal-title":"Eur J Pharm Sci"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.arr.2012.06.003","volume":"12","author":"Martin L.","year":"2013","unstructured":"Martin L.; Latypova X.; Wilson C.M.; Magnaudeix A.; Perrin M.L.; Yardin C.; Terro F.; Tau protein kinases: Involvement in Alzheimer\u2019s disease. Ageing Res Rev 2013,12(1),289-309","journal-title":"Ageing Res Rev"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"648982","DOI":"10.3389\/fnagi.2021.648982","volume":"13","author":"Oizumi H.","year":"2021","unstructured":"Oizumi H.; Yamasaki K.; Suzuki H.; Hasegawa T.; Sugimura Y.; Baba T.; Fukunaga K.; Takeda A.; Fatty Acid-Binding Protein 3 Expression in the Brain and Skin in Human Synucleinopathies. Front Aging Neurosci 2021,13,648982","journal-title":"Front Aging Neurosci"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41401-021-00675-8","volume":"43","author":"Cheng A.","year":"2022","unstructured":"Cheng A.; Wang Y.; Shinoda Y.; Kawahata I.; Yamamoto T.; Jia W.; Yamamoto H.; Mizobata T.; Kawata Y.; Fukunaga K.; Fatty acid-binding protein 7 triggers \u03b1-synuclein oligomerization in glial cells and oligodendrocytes associated with oxidative stress. Acta Pharmacol Sin 2022,43(3),552-562","journal-title":"Acta Pharmacol Sin"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"5358","DOI":"10.3390\/ijms20215358","volume":"20","author":"Kawahata I.","year":"2019","unstructured":"Kawahata I.; Bousset L.; Melki R.; Fukunaga K.; Fatty Acid-Binding Protein 3 is Critical for \u03b1-Synuclein Uptake and MPP-Induced Mitochondrial Dysfunction in Cultured Dopaminergic Neurons. Int J Mol Sci 2019,20(21),5358","journal-title":"Int J Mol Sci"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.neuropharm.2018.08.027","volume":"147","author":"Parsons C.G.","year":"2019","unstructured":"Parsons C.G.; CNS repurposing - Potential new uses for old drugs: Examples of screens for Alzheimer\u2019s disease, Parkinson\u2019s disease and spasticity. Neuropharmacology 2019,147,4-10","journal-title":"Neuropharmacology"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1139\/cjpp-2016-0158","volume":"95","author":"Ameen A.M.","year":"2017","unstructured":"Ameen A.M.; Elkazaz A.Y.; Mohammad H.M.F.; Barakat B.M.; Anti-inflammatory and neuroprotective activity of boswellic acids in rotenone parkinsonian rats. Can J Physiol Pharmacol 2017,95(7),819-829","journal-title":"Can J Physiol Pharmacol"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"5207","DOI":"10.1016\/j.bmcl.2017.10.048","volume":"27","author":"Kim S.M.","year":"2017","unstructured":"Kim S.M.; Park Y.J.; Shin M.S.; Kim H.R.; Kim M.J.; Lee S.H.; Yun S.P.; Kwon S.H.; Acacetin inhibits neuronal cell death induced by 6-hydroxydopamine in cellular Parkinson\u2019s disease model. Bioorg Med Chem Lett 2017,27(23),5207-5212","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.bmcl.2018.12.028","volume":"29","author":"Derf A.","year":"2019","unstructured":"Derf A.; Sharma A.; Bharate S.B.; Chaudhuri B.; Aegeline, a natural product from the plant Aegle marmelos, mimics the yeast SNARE protein Sec22p in suppressing \u03b1-synuclein and Bax toxicity in yeast. Bioorg Med Chem Lett 2019,29(3),454-460","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1007\/s11064-017-2183-2","volume":"42","author":"Nataraj J.","year":"2017","unstructured":"Nataraj J.; Manivasagam T.; Justin Thenmozhi A.; Essa M.M.; Neurotrophic Effect of Asiatic acid, a Triterpene of Centella asiatica Against Chronic 1-Methyl 4-Phenyl 1, 2, 3, 6-Tetrahydropyridine Hydrochloride\/Probenecid Mouse Model of Parkinson\u2019s disease: The Role of MAPK, PI3K-Akt-GSK3\u03b2 and mTOR Signalling Pathways. Neurochem Res 2017,42(5),1354-1365","journal-title":"Neurochem Res"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/aps.2016.42","volume":"37","author":"Ren Z.","year":"2016","unstructured":"Ren Z.; Zhao Y.; Cao T.; Zhen X.; Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson\u2019s disease by suppressing glycogen synthase kinase-3 beta activity. Acta Pharmacol Sin 2016,37(10),1315-1324","journal-title":"Acta Pharmacol Sin"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11010-016-2733-y","volume":"418","author":"Ojha S.","year":"2016","unstructured":"Ojha S.; Javed H.; Azimullah S.; Haque M.E.; \u03b2-Caryophyllene, a phytocannabinoid attenuates oxidative stress, neuroinflammation, glial activation, and salvages dopaminergic neurons in a rat model of Parkinson disease. Mol Cell Biochem 2016,418(1-2),59-70","journal-title":"Mol Cell Biochem"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3389\/fnins.2017.00272","volume":"11","author":"Hu J.","year":"2017","unstructured":"Hu J.; Ferchmin P.A.; Hemmerle A.M.; Seroogy K.B.; Eterovic V.A.; Hao J.; 4R-Cembranoid Improves Outcomes after 6-Hydroxydopamine Challenge in Both In vitro and In vivo Models of Parkinson\u2019s Disease. Front Neurosci 2017,11,272","journal-title":"Front Neurosci"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12640-017-9748-3","volume":"32","author":"Alvari\u00f1o R.","year":"2017","unstructured":"Alvari\u00f1o R.; Alonso E.; Tribalat M.A.; Gegunde S.; Thomas O.P.; Botana L.M.; Evaluation of the Protective Effects of Sarains on HO-Induced Mitochondrial Dysfunction and Oxidative Stress in SH-SY5Y Neuroblastoma Cells. Neurotox Res 2017,32(3),368-380","journal-title":"Neurotox Res"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1021\/cn500258c","volume":"6","author":"Leir\u00f3s M.","year":"2015","unstructured":"Leir\u00f3s M.; Alonso E.; Rateb M.E.; Houssen W.E.; Ebel R.; Jaspars M.; Alfonso A.; Botana L.M.; Bromoalkaloids protect primary cortical neurons from induced oxidative stress. ACS Chem Neurosci 2015,6(2),331-338","journal-title":"ACS Chem Neurosci"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3390\/md15080246","volume":"15","author":"Boccitto M.","year":"2017","unstructured":"Boccitto M.; Lee N.; Sakamoto S.; Spruce L.; Handa H.; Clardy J.; Seeholzer S.; Kalb R.; The neuroprotective marine compound psammaplysene A binds the RNA-binding protein HNRNPK. Mar Drugs 2017,15(8),246","journal-title":"Mar Drugs"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1021\/acs.jnatprod.5b00987","volume":"79","author":"Wang D.","year":"2016","unstructured":"Wang D.; Feng Y.; Murtaza M.; Wood S.; Mellick G.; Hooper J.N.A.; Quinn R.J.; A Grand Challenge: Unbiased Phenotypic Function of Metabolites from Jaspis splendens against Parkinson\u2019s Disease. J Nat Prod 2016,79(2),353-361","journal-title":"J Nat Prod"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3390\/ijms18051096","volume":"18","author":"Kao C.J.","year":"2017","unstructured":"Kao C.J.; Chen W.F.; Guo B.L.; Feng C.W.; Hung H.C.; Yang W.Y.; Sung C.S.; Tsui K.H.; Chu H.; Chen N.F.; Wen Z.H.; The 1-tosylpentan-3-one protects against 6-hydroxydopamine-induced neurotoxicity. Int J Mol Sci 2017,18(5),1096","journal-title":"Int J Mol Sci"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jff.2018.04.035","volume":"46","author":"Wang X.","year":"2018","unstructured":"Wang X.; Cong P.; Liu Y.; Tao S.; Chen Q.; Wang J.; Xu J.; Xue C.; Neuritogenic effect of sea cucumber glucocerebrosides on NGF-induced PC12 cells via activation of the TrkA\/CREB\/BDNF signalling pathway. J Funct Foods 2018,46,175-184","journal-title":"J Funct Foods"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"785","DOI":"10.4014\/jmb.1612.12025","volume":"27","author":"Lee H.W.","year":"2017","unstructured":"Lee H.W.; Choi H.; Nam S.J.; Fenical W.; Kim H.; Potent Inhibition of Monoamine Oxidase B by a Piloquinone from Marine-Derived Streptomyces sp. CNQ-027. J Microbiol Biotechnol 2017,27(4),785-790","journal-title":"J Microbiol Biotechnol"},{"key":"ref=165","first-page":"39","volume":"3","author":"Wang W.","year":"2015","unstructured":"Wang W.; Song N.; Jia F.; Xie J.; Zhang Q.; Jiang H.; Neuroprotective effects of porphyran derivatives against 6-hydroxydopamine-induced cytotoxicity is independent on mitochondria restoration. Ann Transl Med 2015,3(3),39","journal-title":"Ann Transl Med"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.ijbiomac.2018.02.029","volume":"112","author":"Souza R.B.","year":"2018","unstructured":"Souza R.B.; Frota A.F.; Silva J.; Alves C.; Neugebauer A.Z.; Pinteus S.; Rodrigues J.A.G.; Cordeiro E.M.S.; de Almeida R.R.; Pedrosa R.; Benevides N.M.B.; In vitro activities of kappa-carrageenan isolated from red marine alga Hypnea musciformis: Antimicrobial, anticancer and neuroprotective potential. Int J Biol Macromol 2018,112,1248-1256","journal-title":"Int J Biol Macromol"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/bcpt.12669","volume":"120","author":"Souza R.B.","year":"2017","unstructured":"Souza R.B.; Frota A.F.; Sousa R.S.; Cezario N.A.; Santos T.B.; Souza L.M.F.; Coura C.O.; Monteiro V.S.; Cristino Filho G.; Vasconcelos S.M.M.; da Cunha R.M.S.; Aguiar L.M.V.; Benevides N.M.B.; Neuroprotective Effects of Sulphated Agaran from Marine Alga Gracilaria cornea in Rat 6-Hydroxydopamine Parkinson\u2019s Disease Model: Behavioural, Neurochemical and Transcriptional Alterations. Basic Clin Pharmacol Toxicol 2017,120(2),159-170","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.3390\/ijms22041888","volume":"22","author":"Silva J.","year":"2021","unstructured":"Silva J.; Alves C.; Martins A.; Susano P.; Sim\u00f5es M.; Guedes M.; Rehfeldt S.; Pinteus S.; Gaspar H.; Rodrigues A.; Goettert M.I.; Alfonso A.; Pedrosa R.; Loliolide, a new therapeutic option for neurological diseases? In vitro neuroprotective and anti-inflammatory activities of a monoterpenoid lactone isolated from codium tomentosum. Int J Mol Sci 2021,22(4),1888","journal-title":"Int J Mol Sci"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"105589","DOI":"10.1016\/j.phrs.2021.105589","volume":"168","author":"Silva J.","year":"2021","unstructured":"Silva J.; Alves C.; Pinteus S.; Susano P.; Sim\u00f5es M.; Guedes M.; Martins A.; Rehfeldt S.; Gaspar H.; Goettert M.; Alfonso A.; Pedrosa R.; Disclosing the potential of eleganolone for Parkinson\u2019s disease therapeutics: Neuroprotective and anti-inflammatory activities. Pharmacol Res 2021,168,105589","journal-title":"Pharmacol Res"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jff.2019.04.017","volume":"57","author":"Ye Q.","year":"2019","unstructured":"Ye Q.; Wang W.; Hao C.; Mao X.; Agaropentaose protects SH-SY5Y cells against 6-hydroxydopamine-induced neurotoxicity through modulating NF-\u03baB and p38MAPK signaling pathways. J Funct Foods 2019,57,222-232","journal-title":"J Funct Foods"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"595254","DOI":"10.3389\/fphar.2020.595254","volume":"11","author":"Shen Y.","year":"2020","unstructured":"Shen Y.; Zhang B.; Pang X.; Yang R.; Chen M.; Zhao J.; Wang J.; Wang Z.; Yu Z.; Wang Y.; Li L.; Liu A.; Du G.; Network Pharmacology-Based Analysis of Xiao-Xu-Ming Decoction on the Treatment of Alzheimer\u2019s Disease. Front Pharmacol 2020,11,595254","journal-title":"Front Pharmacol"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/2025914","volume":"2018","author":"Liu P.","year":"2018","unstructured":"Liu P.; Chen X.; Zhou H.; Wang L.; Zhang Z.; Ren X.; Zhu F.; Guo Y.; Huang X.; Liu J.; Spencer P.S.; Yang X.; The isoquinoline alkaloid dauricine targets multiple molecular pathways to ameliorate Alzheimer-like pathological changes in vitro. Oxid Med Cell Longev 2018,2018,1-19","journal-title":"Oxid Med Cell Longev"},{"key":"ref=173","author":"Huang D. S.","unstructured":"Huang D. S.; Protective Effects of Wogonin against Alzheimer\u2019s Disease by Inhibition of Amyloidogenic Pathway. Evidence-based Complement Altern Med 2017: 2017: 3545169.","journal-title":"Evidence-based Complement Altern Med"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1021\/acs.jnatprod.9b00964","volume":"83","author":"Cho H.M.","year":"2020","unstructured":"Cho H.M.; Ha T.K.Q.; Doan T.P.; Dhodary B.; An J.P.; Lee B.W.; Yang J.L.; Oh W.K.; Neuroprotective Effects of Triterpenoids from Camellia japonica against Amyloid \u03b2-Induced Neuronal Damage. J Nat Prod 2020,83(7),2076-2086","journal-title":"J Nat Prod"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"103489","DOI":"10.1016\/j.bioorg.2019.103489","volume":"95","author":"Wang Y.M.","year":"2020","unstructured":"Wang Y.M.; Ming W.Z.; Liang H.; Wang Y.J.; Zhang Y.H.; Meng D.L.; Isoquinolines from national herb Corydalis tomentella and neuroprotective effect against lipopolysaccharide-induced BV2 microglia cells. Bioorg Chem 2020,95,103489","journal-title":"Bioorg Chem"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.phytochem.2018.10.028","volume":"157","author":"Xia C.L.","year":"2019","unstructured":"Xia C.L.; Tang G.H.; Guo Y.Q.; Xu Y.K.; Huang Z.S.; Yin S.; Mulberry Diels-Alder-type adducts from Morus alba as multi-targeted agents for Alzheimer\u2019s disease. Phytochemistry 2019,157,82-91","journal-title":"Phytochemistry"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3389\/fnmol.2018.00437","volume":"11","author":"Zhang Q.","year":"2018","unstructured":"Zhang Q.; Xia Y.; Luo H.; Huang S.; Wang Y.; Shentu Y.; Mahaman Y.A.R.; Huang F.; Ke D.; Wang Q.; Liu R.; Wang J.Z.; Zhang B.; Wang X.; Codonopsis pilosula polysaccharide attenuates tau hyperphosphorylation and cognitive impairments in htau infected mice. Front Mol Neurosci 2018,11,437","journal-title":"Front Mol Neurosci"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/biof.1422","volume":"44","author":"Dhouafli Z.","year":"2018","unstructured":"Dhouafli Z.; Leri M.; Bucciantini M.; Stefani M.; Gadhoumi H.; Mahjoub B.; Ben Jannet H.; Guillard J.; Ksouri R.; Saidani Tounsi M.; Soto C.; Hayouni E.A.; 1,2,4-trihydroxynaphthalene-2-O-\u03b2-D-glucopyranoside delays amyloid-\u03b2 aggregation and reduces amyloid cytotoxicity. Biofactors 2018,44(3),272-280","journal-title":"Biofactors"},{"key":"ref=179","first-page":"956","volume":"43","author":"Wang C.","year":"2019","unstructured":"Wang C.; Cai X.; Hu W.; Li Z.; Kong F.; Chen X.; Wang D.; Investigation of the neuroprotective effects of crocin via antioxidant activities in HT22 cells and in mice with Alzheimer\u2019s disease. Int J Mol Med 2019,43(2),956-966","journal-title":"Int J Mol Med"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ijbiomac.2018.10.021","volume":"121","author":"Gan S.Y.","year":"2019","unstructured":"Gan S.Y.; Wong L.Z.; Wong J.W.; Tan E.L.; Fucosterol exerts protection against amyloid \u03b2-induced neurotoxicity, reduces intracellular levels of amyloid \u03b2 and enhances the mRNA expression of neuroglobin in amyloid \u03b2-induced SH-SY5Y cells. Int J Biol Macromol 2019,121,207-213","journal-title":"Int J Biol Macromol"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1021\/acschemneuro.7b00527","volume":"9","author":"Wang J.","year":"2018","unstructured":"Wang J.; Zheng J.; Huang C.; Zhao J.; Lin J.; Zhou X.; Naman C.B.; Wang N.; Gerwick W.H.; Wang Q.; Yan X.; Cui W.; He S.; Eckmaxol, a Phlorotannin Extracted from Ecklonia maxima, Produces Anti-\u03b2-amyloid Oligomer Neuroprotective Effects Possibly via Directly Acting on Glycogen Synthase Kinase 3\u03b2. ACS Chem Neurosci 2018,9(6),1349-1356","journal-title":"ACS Chem Neurosci"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3390\/md16100368","volume":"16","author":"Oh J.","year":"2018","unstructured":"Oh J.; Choi J.; Nam T.J.; Fucosterol from an edible brown alga ecklonia stolonifera prevents soluble amyloid beta-induced cognitive dysfunction in aging rats. Mar Drugs 2018,16(10),368","journal-title":"Mar Drugs"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/6792543","volume":"2017","author":"Lin J.","year":"2017","unstructured":"Lin J.; Yu J.; Zhao J.; Zhang K.; Zheng J.; Wang J.; Huang C.; Zhang J.; Yan X.; Gerwick W.H.; Wang Q.; Cui W.; He S.; Fucoxanthin, a Marine Carotenoid, Attenuates \u03b2 -Amyloid Oligomer-Induced Neurotoxicity Possibly via Regulating the PI3K\/Akt and the ERK Pathways in SH-SY5Y Cells. Oxid Med Cell Longev 2017,2017,1-10","journal-title":"Oxid Med Cell Longev"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1021\/acs.jafc.7b00805","volume":"65","author":"Xiang S.","year":"2017","unstructured":"Xiang S.; Liu F.; Lin J.; Chen H.; Huang C.; Chen L.; Zhou Y.; Ye L.; Zhang K.; Jin J.; Zhen J.; Wang C.; He S.; Wang Q.; Cui W.; Zhang J.; Fucoxanthin Inhibits \u03b2-Amyloid Assembly and Attenuates \u03b2-Amyloid Oligomer-Induced Cognitive Impairments. J Agric Food Chem 2017,65(20),4092-4102","journal-title":"J Agric Food Chem"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3390\/md15030077","volume":"15","author":"Wei H.","year":"2017","unstructured":"Wei H.; Gao Z.; Zheng L.; Zhang C.; Liu Z.; Yang Y.; Teng H.; Hou L.; Yin Y.; Zou X.; Protective effects of fucoidan on A\u03b225-35 and D-gal-induced neurotoxicity in PC12 cells and D-gal-induced cognitive dysfunction in mice. Mar Drugs 2017,15(3),77","journal-title":"Mar Drugs"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3892\/mmr.2016.6006","volume":"15","author":"Liu Y.","year":"2017","unstructured":"Liu Y.; Jiang L.; Li X.; \u03ba-carrageenan-derived pentasaccharide attenuates A\u03b225\u201335-induced apoptosis in SH-SY5Y cells via suppression of the JNK signaling pathway. Mol Med Rep 2017,15(1),285-290","journal-title":"Mol Med Rep"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1039\/C7FO00662D","volume":"9","author":"Wang X.","year":"2018","unstructured":"Wang X.; Yi K.; Zhao Y.; Fucoidan inhibits amyloid-\u03b2-induced toxicity in transgenic Caenorhabditis elegans by reducing the accumulation of amyloid-\u03b2 and decreasing the production of reactive oxygen species. Food Funct 2018,9(1),552-560","journal-title":"Food Funct"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.freeradbiomed.2018.08.016","volume":"126","author":"Yang E.J.","year":"2018","unstructured":"Yang E.J.; Mahmood U.; Kim H.; Choi M.; Choi Y.; Lee J.P.; Cho J.Y.; Hyun J.W.; Kim Y.S.; Chang M.J.; Kim H.S.; Phloroglucinol ameliorates cognitive impairments by reducing the amyloid \u03b2 peptide burden and pro-inflammatory cytokines in the hippocampus of 5XFAD mice. Free Radic Biol Med 2018,126,221-234","journal-title":"Free Radic Biol Med"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.niox.2019.07.009","volume":"91","author":"Shanmuganathan B.","year":"2019","unstructured":"Shanmuganathan B.; Sathya S.; Balasubramaniam B.; Balamurugan K.; Devi K.P.; Amyloid-\u03b2 induced neuropathological actions are suppressed by Padina gymnospora (Phaeophyceae) and its active constituent \u03b1-bisabolol in Neuro2a cells and transgenic Caenorhabditis elegans Alzheimer\u2019s model. Nitric Oxide 2019,91,52-66","journal-title":"Nitric Oxide"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3390\/md19040190","volume":"19","author":"Martens N.","year":"2021","unstructured":"Martens N.; Schepers M.; Zhan N.; Leijten F.; Voortman G.; Tiane A.; Rombaut B.; Poisquet J.; Sande N.; Kerksiek A.; Kuipers F.; Jonker J.W.; Liu H.; L\u00fctjohann D.; Vanmierlo T.; Mulder M.T.; 24(S)-Saringosterol Prevents Cognitive Decline in a Mouse Model for Alzheimer\u2019s Disease. Mar Drugs 2021,19(4),190","journal-title":"Mar Drugs"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/1755-0998.13102","volume":"20","author":"Cao M.","year":"2020","unstructured":"Cao M.; Xu K.; Yu X.; Bi G.; Liu Y.; Kong F.; Sun P.; Tang X.; Du G.; Ge Y.; Wang D.; Mao Y.; A chromosome-level genome assembly of Pyropia haitanensis (Bangiales, Rhodophyta). Mol Ecol Resour 2020,20(1),216-227","journal-title":"Mol Ecol Resour"},{"key":"ref=192","doi-asserted-by":"crossref","first-page":"e1800707","DOI":"10.1002\/mnfr.201800707","volume":"63","author":"Li Q.","year":"2019","unstructured":"Li Q.; Che H.X.; Wang C.C.; Zhang L.Y.; Ding L.; Xue C.H.; Zhang T.T.; Wang Y.M.; Cerebrosides from Sea Cucumber Improved A\u03b2 -Induced Cognitive Deficiency in a Rat Model of Alzheimer\u2019s Disease. Mol Nutr Food Res 2019,63(5),e1800707","journal-title":"Mol Nutr Food Res"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jff.2017.03.030","volume":"33","author":"Wang X.","year":"2017","unstructured":"Wang X.; Tao S.; Cong P.; Wang Y.; Xu J.; Xue C.; Neuroprotection of Strongylocentrotus nudus gangliosides against Alzheimer\u2019s disease via regulation of neurite loss and mitochondrial apoptosis. J Funct Foods 2017,33,122-133","journal-title":"J Funct Foods"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1021\/acs.molpharmaceut.8b01090","volume":"16","author":"Alvari\u00f1o R.","year":"2019","unstructured":"Alvari\u00f1o R.; Alonso E.; Lacret R.; Oves-Costales D.; Genilloud O.; Reyes F.; Alfonso A.; Botana L.M.; Caniferolide A, a Macrolide from Streptomyces caniferus, Attenuates Neuroinflammation, Oxidative Stress, Amyloid-Beta, and Tau Pathology In vitro. Mol Pharm 2019,16(4),1456-1466","journal-title":"Mol Pharm"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.neuropharm.2018.09.008","volume":"141","author":"Alvari\u00f1o R.","year":"2018","unstructured":"Alvari\u00f1o R.; Alonso E.; Lacret R.; Oves-Costales D.; Genilloud O.; Reyes F.; Alfonso A.; Botana L.M.; Streptocyclinones A and B ameliorate Alzheimer\u2019s disease pathological processes in vitro. Neuropharmacology 2018,141,283-295","journal-title":"Neuropharmacology"}],"container-title":["Frontiers in Clinical Drug Research - CNS and Neurological Disorders","Frontiers in Clinical Drug Research - CNS and Neurological Disorders: Volume 12"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T15:20:48Z","timestamp":1713194448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/node\/227870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,10]]},"ISBN":["9789815179842"],"references-count":195,"URL":"https:\/\/doi.org\/10.2174\/9789815179842124120003","relation":{},"ISSN":["2214-7527"],"issn-type":[{"value":"2214-7527","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,10]]}}}